Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates

Bristol Myers (BMY) delivered earnings and revenue surprises of 11.64% and 0.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BMY : 61.33 (+2.75%)
Bristol-Myer Sqb Set to Possibly Pullback After Yesterday's Rally of 3.20%

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $60.42 to a high of $62.97. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of...

BMY : 61.33 (+2.75%)
Bristol Myers: 2Q Earnings Snapshot

NEW YORK (AP) _ Bristol Myers Squibb Co. (BMY) on Thursday reported a second-quarter loss of $85 million, after reporting a profit in the same period a year earlier.

BMY : 61.33 (+2.75%)
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up

Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.

PFE : 38.27 (-0.47%)
MRK : 81.05 (-0.72%)
BMY : 61.33 (+2.75%)
XLRN : 106.46 (-0.08%)
Global PD-L1 NSCLC Market: Insights, Epidemiology, Drugs and Players (2017-2030)

, /PRNewswire/ -- The drug pipelines has been added to offering.

BMY : 61.33 (+2.75%)
GSK : 40.97 (-0.58%)
MRK : 81.05 (-0.72%)
MKKGY : 26.8500 (+1.97%)
NVS : 83.41 (-0.01%)
REGN : 621.21 (-0.53%)
Bristol Myers Squibb Reports Second Quarter 2020 Financial Results

Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance.

BMY : 61.33 (+2.75%)
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress

--- Elivaldogene autotemcel (eli-cel, Lenti-D gene therapy) in cerebral adrenoleukodystrophy (CALD) granted accelerated assessment of Marketing Authorization Application (MAA) from EMA -

BLUE : 63.84 (+2.87%)
BMY : 61.33 (+2.75%)
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

MRK : 81.05 (-0.72%)
BMY : 61.33 (+2.75%)
BLRX : 1.9100 (-18.69%)
CORT : 13.97 (-2.72%)
Want To Retire Early? Learn the Intelligent Investing Secret - August 05, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments,...

ABBV : 92.57 (-0.73%)
BMY : 61.33 (+2.75%)
AMGN : 241.55 (+0.03%)
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

BMY : 61.33 (+2.75%)
ARCT : 56.08 (-0.09%)
BLUE : 63.84 (+2.87%)
MEIP : 2.72 (-2.51%)
Grab These 4 High Earnings Yield Stocks for Solid Returns

While comparing stocks, if other factors are similar, the stock with a higher earnings yield is considered undervalued.

BMY : 61.33 (+2.75%)
MTH : 100.59 (-1.00%)
ABG : 103.91 (-2.05%)
PFSI : 50.49 (+1.02%)
Is a Surprise Coming for Bristol-Myers (BMY) This Earnings Season?

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BMY : 61.33 (+2.75%)
Next Support Level for Bristol-Myer Sqb (BMY) is $58.54

Bristol-Myer Sqb (NYSE:BMY) has opened bearishly below the pivot of $59.23 today and has reached the first level of support at $58.82. Should the shares continue to fall, the support pivots of $58.54...

BMY : 61.33 (+2.75%)
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

BMY : 61.33 (+2.75%)
TBIO : 15.22 (+0.33%)
PCRX : 58.13 (+3.62%)
ALDX : 6.76 (-9.38%)
Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

RHHBY : 43.4300 (+0.07%)
BMRN : 119.65 (-0.15%)
MRK : 81.05 (-0.72%)
BMY : 61.33 (+2.75%)
Orphan Drugs Market to Reach USD 340.84 Billion by 2027; Increasing Incidence of Life-threatening Diseases will Bode well for Market Growth, says Fortune Business Insights(TM)

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market...

ALXN : 103.90 (+1.12%)
BAYRY : 16.6200 (-0.48%)
BMY : 61.33 (+2.75%)
GSK : 40.97 (-0.58%)
NVO : 63.69 (-2.15%)
3 Reasons Why Growth Investors Shouldn't Overlook Bristol Myers (BMY)

Bristol Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.

BMY : 61.33 (+2.75%)
Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

MRK : 81.05 (-0.72%)
INCY : 97.25 (-0.38%)
BMY : 61.33 (+2.75%)
TBIO : 15.22 (+0.33%)
BMY vs. HZNP: Which Stock Should Value Investors Buy Now?

BMY vs. HZNP: Which Stock Is the Better Value Option?

BMY : 61.33 (+2.75%)
HZNP : 72.22 (-5.45%)
Signs That Your Trading Will Ruin Your Retirement - August 03, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

ABBV : 92.57 (-0.73%)
BMY : 61.33 (+2.75%)
AMGN : 241.55 (+0.03%)

Van Meerten Stock Picks

The 5 Best Large Caps
Today I wanted to find the 5 best Large Caps per my screening criteria.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar